Arax Advisory Partners’s Alaunos Therapeutics TCRT Stock Holding History

Arax Advisory Partners’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.75K	Buy	+1,216	New	+$3.11K	﹤0.01%	4742

Other funds holding TCRT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Arax Advisory Partners's TCRT Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Alaunos Therapeutics (TCRT) in Q2 2026: 1,216 shares worth $2.75K. The stake represents ﹤0.01% of the portfolio and ranks #4742 among its holdings.

22 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

Arax Advisory Partners held 1,216 shares of Alaunos Therapeutics worth $2.75K as of Q2 2026.
Alaunos Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Alaunos Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4742 holding.
22 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.